Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response.

被引：0

作者：

Chung, Andrew W. ^{[1
]}

Anand, Kartik ^{[2
]}

Niravath, Polly ^{[3
]}

Gupta, Nakul ^{[3
]}

Venta, Luz A. ^{[3
]}

Schwartz, Mary R. ^{[3
]}

Qian, Wei ^{[3
]}

Xu, Yitian ^{[3
]}

Zhang, Licheng ^{[3
]}

Chen, Qiuying ^{[4
]}

Attarwala, Nabeel ^{[4
]}

Kuhn, John ^{[5
]}

Patel, Tejal A. ^{[6
]}

Rodriguez, Angel ^{[7
]}

Belcheva, Anna ^{[3
]}

Darcourt, Jorge ^{[3
]}

Ensor, Joe E. ^{[3
]}

Bernicker, Eric ^{[3
]}

Pan, Ping-Ying ^{[3
]}

Kaklamani, Virginia ^{[5
]}

Chen, Shu-Hsia ^{[3
]}

Chang, Jenny C. ^{[3
]}

机构：

[1] Texas A&M Univ, Houston, TX USA

[2] Great Plains Hlth, North Platte, NE USA

[3] Houston Methodist Canc Ctr, Houston, TX USA

[4] Weill Cornell Med, New York, NY USA

[5] Univ Texas, Hlth Sci Ctr San Antonio, San Antonio, TX USA

[6] MD Anderson Canc Ctr, Houston, TX USA

[7] Austin Canc Ctr, Austin, TX USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT175

引用

页数：2

共 42 条

[21] Oncometabolite D-2HG drives tumor metastasis and protumoral macrophage polarization by targeting FTO/m6A/ANGPTL4/integrin axis in triple-negative breast cancer
Zhang, Siyue
Zhang, Ning
Wan, Tong
He, Yinqiao
Hao, Jie
Liu, Yiwei
Liu, Yidong
Chen, Bing
Zhao, Wenjing
Wang, Lijuan
Luo, Dan
Gao, Chao
Yang, Qifeng
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
[22] PTGR1-mediated immune evasion mechanisms in late-stage triple-negative breast cancer: mechanisms of M2 macrophage infiltration and CD8+ T cell suppression
Huang, Fang
Wang, Fuhe
Hu, Qilu
Li, Ying
Jiang, Da
APOPTOSIS, 2024, 29 (11-12) : 2002 - 2024
[23] Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
Spring, Laura
Tolaney, Sara M.
Desai, Neelam Vijay
Fell, Geoffrey
Trippa, Lorenzo
Comander, Amy H.
Mulvey, Therese Marie
McLaughlin, Shannon
Ryan, Phoebe
Rosenstock, Aron S.
Garrido-Castro, Ana Christina
Lynce, Filipa
Moy, Beverly
Isakoff, Steven J.
Tung, Nadine M.
Mittendorf, Elizabeth A.
Ellisen, Leif W.
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Luminal androgen receptor subtype and M2 macrophage signatures strongly associate with low pathological complete response rates and poor outcomes in patients with triple negative breast cancer receiving neoadjuvant chemotherapy
Meisel, Jane
Douglass, Eugene
Kalinsky, Kevin
Griffiths, Lyra M.
Li, Zaibo
Li, Xiaoxian
CANCER RESEARCH, 2023, 83 (05)
[25] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Dillon, Patrick
Basho, Reva
Han, Hyo S.
Kolberg, Hans-Christian
Tkaczuk, Katherine
Zahrah, George
Gion, Maria
Voss, Herman
Meisel, Jane
Pluard, Timothy
Fox, Jenny
Oliveira, Mafalda
Brown-Glaberman, Ursa
Stringer-Reasor, Erica
Manso, Luis
Kuemmel, Sherko
Chen, Lin Chi
Wu, Sheng
Croft, Brandon
Boni, Valentina
CANCER RESEARCH, 2023, 83 (05)
[26] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Meisel, Jane Lowe
Pluard, Timothy J.
Vinayak, Shaveta
Stringer-Reasor, Erica Michelle
Brown-Glaberman, Ursa
Dillon, Patrick Michael
Basho, Reva K.
Varadarajan, Ramya
O'Shaughnessy, Joyce
Han, Hyo S.
Sinha, Rajni
Fox, Jenny R.
Villanueva, Rafael
Chen, Lin Chi
Wu, Sheng
Li, Hong
Tran, Sinhan
Manso, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Adams, Sylvia
Diamond, Jennifer R.
Hamilton, Erika
Pohlmann, Paula R.
Tolaney, Sara M.
Chang, Ching-Wei
Zhang, Wei
Iizuka, Koho
Foster, Paul G.
Molinero, Luciana
Funke, Roel
Powderly, John
JAMA ONCOLOGY, 2019, 5 (03) : 334 - 342
[28] Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
Tedesco, K. L.
Blum, J. L.
Goncalves, A.
Lubinski, J.
Osborne, C. R. C.
Lardelli, P.
Tercero, J. C.
Florez, A.
Holmes, F. A.
Delaloge, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29] Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
Cortes, Maria
Salgado, Alfonso Cortes
Murillo, Serafin Morales
Blancas, Isabel
Cortez, Patricia
Plaza, Isabel Calvo
Fernandez, Nieves Diaz
Martinez-Bueno, Alejandro
Ruiz-Borrego, Manuel
Blanch, Salvador
Llabres, Elisenda
Marme, Frederik
Schmid, Peter
Guarneri, Valentina
Gligorov, Joseph
Perez-Garcia, Jose Manuel
Sampayo-Cordero, Miguel
Malfettone, Andrea
Cussac, Antonio Llombart
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
Yardley, D.
Coleman, R.
Conte, P.
Cortes, J.
Brufsky, A.
Shtivelband, M.
Young, R.
Bengala, C.
Ali, H.
Eakel, J.
Schneeweiss, A.
Merino, L. de la Cruz
Wilks, S.
O'Shaugnessy, J.
Gluck, S.
Li, H.
Beck, R.
Barton, D.
Harbeck, N.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →